Vertex Pharmaceuticals Incorporated
VRTX
$424.99
-$4.61-1.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -988.90M | -535.60M | -479.80M | -489.90M | 4.02B |
| Total Depreciation and Amortization | 176.90M | 182.00M | 207.90M | 196.80M | 184.20M |
| Total Amortization of Deferred Charges | 25.20M | 25.20M | 11.80M | 11.80M | 11.80M |
| Total Other Non-Cash Items | 719.10M | 350.60M | 211.00M | 99.40M | 3.90M |
| Change in Net Operating Assets | -912.60M | -514.80M | -793.50M | -762.10M | -275.30M |
| Cash from Operations | -980.30M | -492.60M | -842.60M | -944.00M | 3.94B |
| Capital Expenditure | -270.00M | -297.70M | -263.20M | -236.10M | -226.70M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1.42B | -3.47B | -3.57B | -3.37B | -3.22B |
| Cash from Investing | -1.69B | -3.77B | -3.83B | -3.60B | -3.44B |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -21.70M | -33.60M | -44.30M | -50.20M | -47.50M |
| Issuance of Common Stock | 114.40M | 114.60M | 126.70M | 133.70M | 137.30M |
| Repurchase of Common Stock | -1.91B | -1.58B | -1.31B | -1.09B | -719.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 3.50M | 6.20M | 3.80M | 4.00M | 4.20M |
| Cash from Financing | -1.82B | -1.49B | -1.22B | -1.00B | -625.00M |
| Foreign Exchange rate Adjustments | 3.50M | -42.60M | 32.10M | -13.20M | -700.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.48B | -5.80B | -5.87B | -5.56B | -126.20M |